Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | September 18, 2017
September 18, 2017 — Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017
September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons | September 13, 2017
September 13, 2017 — Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from...
Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons | August 29, 2017
August 29, 2017 — C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted...
News | Drug-Eluting Balloons | August 15, 2017
August 15, 2017 — Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons | July 26, 2017
July 26, 2017 — The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market...
Philips acquires purchases Spectranetics
Feature | Cardiovascular Business | June 28, 2017
June 28, 2017 — Philips Healthcare and Spectranetics Corp. announced they have entered into a definitive merger...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study of...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons | April 26, 2017
April 26, 2017 — Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA...
Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch
News | Peripheral Artery Disease (PAD) | March 09, 2017
March 9, 2017 — Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons | February 08, 2017
February 8, 2017 — Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and...
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons | December 06, 2016
December 6, 2016 — The Spectranetics Corp. announced in late November that its Stellarex 0.014-inch drug-coated...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons | September 26, 2016
September 26, 2016 — C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons | September 22, 2016
September 22, 2016 — New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the...